ImmunityBio, Inc. (IBRX)

7,65 -0,10 (-1,29%) Alla chiusura: 04:00PM EDT

ImmunityBio, Inc.

3530 John Hopkins Court
San Diego, CA 92121
United States
844 696 5235
https://immunitybio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 628

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.	Executive Chairman of the Board and Global Chief Scientific & Medical Officer	865,34k	N/D	1953
Mr. Richard Gerald Adcock	President, CEO & Director	1,16M	N/D	1969
Mr. David C. Sachs	Chief Financial Officer	824,62k	N/D	1978
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director	N/D	N/D	1965
Dr. Leonard S. Sender M.D.	Chief Operating Officer	N/D	N/D	N/D
Ms. Regan J. Lauer	Chief Accounting Officer	N/D	N/D	1970
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer	N/D	N/D	1967
Mr. Jason R. Liljestrom	General Counsel & Corporate Secretary	N/D	N/D	1983
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	N/D	N/D	N/D
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di ImmunityBio, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 6; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.